# A Study of Enzastaurin in Chinese Patients With Advanced and/or Metastatic Solid Tumors or Lymphoma

> **NCT01432951** · PHASE1 · COMPLETED · sponsor: **Eli Lilly and Company** · enrollment: 26 (actual)

## Conditions studied

- Solid Tumor
- Lymphoma, Malignant

## Interventions

- **DRUG:** Enzastaurin

## Key facts

- **NCT ID:** NCT01432951
- **Lead sponsor:** Eli Lilly and Company
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2011-11
- **Primary completion:** 2013-01-11
- **Final completion:** 2018-01-05
- **Target enrollment:** 26 (ACTUAL)
- **Last updated:** 2020-10-12


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01432951

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01432951, "A Study of Enzastaurin in Chinese Patients With Advanced and/or Metastatic Solid Tumors or Lymphoma". Retrieved via AI Analytics 2026-06-25 from https://api.ai-analytics.org/clinical/NCT01432951. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*